Merck & Co. Inc. (NYSE:MRK) Working On Vaccine

XCSFDHG46767FHJHJF

tdp2664 E money daily Merck & Co. Inc. (NYSE:MRK), the drugmaker, has plans to work with the Serum Institute on pneumococcal vaccine for children. Merck & Co. Inc. (NYSE:MRK) Working On Vaccine Merck & Co. Inc. (NYSE:MRK) has announced that it will work with Serum Institute of India Ltd. to extend a children’s pneumococcal vaccine for use in emerging and developing countries. Merck & Co. Inc. (NYSE:MRK) and Serum Institute have declared that they will help supply the development and manufacture of the vaccine and both of them will have the rights to market the vaccine in separate regions. Merck & Co. Inc. (NYSE:MRK) stocks were at 31.51 at the end of the last day’s trading. There’s been a -10.6% change in the stock price over the past 3 months. Merck & Co. Inc. (NYSE:MRK) Analyst Advice Consensus Opinion: Moderate Buy Mean recommendation: 1.65 (1=Strong Buy, 5=Strong Sell) 3 Months Ago: 1.68 Zack’s Rank: 1 out of 14 in the industry